Neurology Pharma Marketing
& Medical Communications India.

Neurology — the most mechanistically complex therapeutic area

Neurology pharma communications operate against the most mechanistically complex scientific terrain of any therapeutic area. CNS pathways are frequently debated. Clinical endpoints are often subjective (depression rating scales, cognitive assessment scales, pain scales) or composite (multi-domain functional measures). Patient populations are heterogeneous — even within named diagnoses, patient subtypes respond very differently to the same therapy. The audience — neurologists, psychiatrists, neurosurgeons, neuromuscular specialists — is sophisticated and sceptical of claims not grounded in mechanism.

Mechanism-driven communications

ICG's neurology communications are built on mechanism first, then on clinical evidence consistent with mechanism, then on commercial differentiation. The reverse sequence — commercial messaging that asks the science to support it — fails with neurology audiences. The mechanism-first discipline pays dividends: neurologists who understand the mechanism are durable prescribers. Neurologists who don't understand the mechanism but were promised an efficacy outcome are ephemeral prescribers.

Subjective and composite endpoints — the interpretation challenge

Neurology efficacy endpoints often combine multiple subjective dimensions. The Hamilton Depression Rating Scale (HDRS), the Montgomery-Åsberg Depression Rating Scale (MADRS), the Mini-Mental State Examination (MMSE), the Expanded Disability Status Scale (EDSS) — each requires nuanced interpretation. A 3-point HDRS improvement is clinically meaningful in some study designs and trivial in others. ICG's neurology medical writing teams are trained to present endpoint changes with their specific clinical context — minimal clinically important difference (MCID) data, responder analysis, and time-to-response characterisation.

Psychiatric drug stigma and patient communication

Psychiatric drug communications in India operate against patient and family stigma that can suppress treatment initiation and adherence. ICG's psychiatric brand patient communications are calibrated for this reality: family-friendly language, normalisation of treatment, focus on functional recovery rather than diagnostic labels, and culturally-sensitive imagery and tone.

Outcome targets

(1) Neurologist and psychiatrist KOL engagement — measurable via paired surveys at 12 months. (2) Mechanism-driven brand narrative consistency — measurable via independent content review. (3) Patient adherence on chronic neuro therapies — measurable on real-world cohorts. (4) Publication impact in neurology journals — Neurology, JAMA Neurology, Lancet Neurology, Journal of Neurology.